Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$15.80 USD
+0.22 (1.41%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $15.78 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Perspective Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -46.51 | 0.00 | -7.27 | -3.39 | -3.45 |
Depreciation/Amortization & Depletion | 0.98 | 0.00 | 0.32 | 0.18 | 0.18 |
Net Change from Assets/Liabilities | 2.30 | 0.00 | -1.85 | -0.07 | -0.84 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6.32 | 0.00 | 1.09 | 0.44 | 0.46 |
Net Cash From Operating Activities | -36.91 | 0.00 | -7.71 | -2.84 | -3.64 |
Property & Equipment | -1.07 | 0.00 | -0.27 | -0.38 | -0.27 |
Acquisition/ Disposition of Subsidiaries | 2.70 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 22.76 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -0.02 | 0.00 | -0.02 | -0.03 | -0.01 |
Net Cash from Investing Activities | 24.37 | 0.00 | -0.28 | -0.41 | -0.29 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.55 | 0.00 | 0.06 | 64.69 | 1.01 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
Other Financing Activities | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.79 | 0.00 | 0.06 | 64.68 | 0.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -11.76 | 0.00 | -7.94 | 61.44 | -2.93 |
Cash at Beginning of Period | 21.18 | 0.00 | 64.01 | 2.57 | 5.51 |
Cash at End of Period | 9.42 | 0.00 | 56.07 | 64.01 | 2.57 |
Diluted Net EPS | -1.70 | -0.50 | -0.50 | -0.30 | -0.50 |
Fiscal Year End for Perspective Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -23.99 | -12.28 | -46.51 | -21.83 | -11.48 |
Depreciation/Amortization & Depletion | 0.92 | 0.35 | 0.98 | 0.71 | 0.46 |
Net Change from Assets/Liabilities | 26.89 | 25.40 | 2.30 | 0.32 | 0.86 |
Net Cash from Discontinued Operations | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.12 | 0.39 | 6.32 | -7.11 | -7.64 |
Net Cash From Operating Activities | 4.95 | 13.85 | -36.91 | -27.91 | -17.80 |
Property & Equipment | -10.09 | -9.07 | -1.07 | -0.98 | -0.76 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 2.70 | 2.70 | 2.70 |
Investments | -40.51 | -38.23 | 22.76 | 22.76 | 22.76 |
Other Investing Activities | 0.00 | 0.00 | -0.02 | -0.02 | -0.02 |
Net Cash from Investing Activities | -50.59 | -47.30 | 24.37 | 24.46 | 24.69 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 288.43 | 63.48 | 0.55 | 0.55 | 0.53 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -0.02 | -0.01 | -0.07 | -0.06 | -0.04 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 102.87 | 0.30 | -0.07 | -0.07 |
Net Cash from Financing Activities | 288.41 | 166.33 | 0.79 | 0.43 | 0.43 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 242.77 | 132.88 | -11.76 | -3.01 | 7.33 |
Cash at Beginning of Period | 9.42 | 9.42 | 21.18 | 21.18 | 21.18 |
Cash at End of Period | 252.19 | 142.30 | 9.42 | 18.17 | 28.50 |
Diluted Net EPS | -0.18 | -0.20 | -0.90 | -0.40 | -0.40 |